Expanded Access Protocol for Cemiplimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma

NCT04154943 ·Status: COMPLETED ·Phase: PHASE2

Real World Study on the Use of Cemiplimab in Adult Patients in UK

NCT05493826 ·Status: COMPLETED

Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

NCT03969004 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC

NCT04242173 ·Status: TERMINATED ·Phase: PHASE2

Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma

NCT04975152 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) Patients

NCT06981325 ·Status: RECRUITING ·Phase: PHASE2

Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma

NCT06585410 ·Status: RECRUITING ·Phase: PHASE3

A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer

NCT05574101 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer

NCT06568172 ·Status: SUSPENDED ·Phase: PHASE3

A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment

NCT06848088 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2

Cemiplimab/Peg-Interferon-α in Advanced CSCC

NCT05729139 ·Status: WITHDRAWN ·Phase: PHASE1

Expanded Access Use of Cemiplimab in Patients With Solid Tumors

NCT06132191 ·Status: APPROVED_FOR_MARKETING

CemiplimAb Survivorship Epidemiology

NCT03836105 ·Status: COMPLETED

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

NCT06246916 ·Status: RECRUITING ·Phase: PHASE3

Cemiplimab for Secondary Angiosarcomas

NCT04873375 ·Status: COMPLETED ·Phase: PHASE2

Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

NCT05352672 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy

NCT03132636 ·Status: COMPLETED ·Phase: PHASE2

Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer

NCT04428671 ·Status: RECRUITING ·Phase: PHASE1

A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer

NCT04315701 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Deep sequencIng in Cutaneous Squamous CEll caRciNomas

NCT05878288 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Next-gen Flow Cytometry to Find Immune Profiles, Treatment Response, and Toxicity Markers in Skin Cancer Patients Treated With Cemiplimab.

NCT07064330 ·Status: RECRUITING

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

NCT05608291 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

NCT06190951 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Anti-PD1-antibody and Pulsed HHI for Advanced BCC

NCT04679480 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma

NCT06594991 ·Status: RECRUITING ·Phase: PHASE2